Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients

American Journal of Hematology

Volumn 89, Issue 6, 2014, Pages 588-590

  Barbui, Tiziano ^a   Thiele, Jürgen ^b   Carobbio, Alessandra ^a   Guglielmelli, Paola ^c   Rambaldi, Alessandro ^a   Vannucchi, Alessandro M ^c   Tefferi, Ayalew ^d  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF FLORENCE   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; HEMOGLOBIN; JANUS KINASE 2;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; WILD TYPE;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; JANUS KINASE 2; MALE; MUTATION; POLYCYTHEMIA VERA; SEX FACTORS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84900852237     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23694     Document Type: Article

References (15)

1. McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol 2007;138:821-822.
2. Swerdlow S, Campo E, Harris N, et al., editors. WHO Classification of Tumours of Haematopoietic and Lympoid Tissues. Lyon, France: IARC Press; 2008.
3. Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): Results of an international study. Am J Hematol 2014;89:52-54.
4. Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014;89:199-202.
5. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005;113:213-219.
6. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 2008;30:336-342.
7. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008;112:2190-2198.
8. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.
9. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myelopropliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
10. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005;366:1945-1953.
11. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of Calreticulin mutations on clinical hematological phenotype and outcome in essential thrombocythemia. Blood, in press.
12. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study of 1, 104 patients. J Clin Oncol 2011;29:3179-3184.
13. Thiele J, Kvasnicka HM, Müllauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification. Blood 2011;117:5710-5718.
14. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood, in press.
15. Chi J, Nicolaou K, Nicolaidou V, et al. Calreticulin exon 9 frame-shift mutations in patients with thrombocytosis. Leukemia, in press.